Advertisement
U.S. Markets closed

NeuroBo Pharmaceuticals, Inc. (NRBO)

NasdaqCM - NasdaqCM Delayed Price. Currency in USD
3.1600+0.2000 (+6.76%)
At close: 04:00PM EDT
3.2800 +0.12 (+3.80%)
After hours: 07:09PM EDT
Full screen
Loading interactive chart...
  • Zacks Small Cap Research

    NRBO: Positive SAD Part 1 Data; MAD Part 2 Results Expected in 1Q25…

    By David Bautz, PhD NASDAQ:NRBO READ THE FULL NRBO RESEARCH REPORT On September 30, 2024, NeuroBo Pharmaceuticals, Inc. (NASDAQ:NRBO) announced positive topline results for the single ascending dose (SAD) Part 1 of the ongoing Phase 1 clinical trial of DA-1726 for the treatment of obesity. A total of 45 obese but otherwise healthy individuals were randomized in a double blind, 6:3 ratio to

  • PR Newswire

    NeuroBo Pharmaceuticals to Participate in Investor Conferences in October

    NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced that management will participate in the following investor conferences in October: